What Are Mesothelioma Biomarkers?

What Biomarkers Are and Why They Matter

A biomarker is a measurable substance in the body that can indicate the presence, progression, or characteristics of a disease. In the context of mesothelioma, biomarkers are proteins, genetic changes, or other molecules that are associated with malignant mesothelioma cells. They are detected through blood tests, tissue analysis, or fluid samples and can provide valuable information that complements imaging and biopsy findings.

The development of reliable mesothelioma biomarkers is an active area of research. Because mesothelioma is difficult to diagnose early and often presents with nonspecific symptoms, a blood test capable of detecting the disease before symptoms appear would be particularly valuable for individuals with known asbestos exposure histories. While no such screening test is currently available, several biomarkers show promise.

Key Blood-Based Biomarkers

Soluble mesothelin-related peptides (SMRP), measured by the MESOMARK assay, is the most extensively studied mesothelioma biomarker. Mesothelin is a protein found on the surface of mesothelial cells, and elevated levels of its soluble form in the blood can indicate the presence of mesothelioma. The MESOMARK test has been approved by the FDA as a monitoring tool to track disease progression and treatment response, though it is not approved for screening or diagnosis.

Osteopontin is a protein involved in cell signaling and immune response that is often elevated in mesothelioma patients. Studies have shown that osteopontin levels can help distinguish asbestos-exposed individuals who have developed mesothelioma from those who have not. However, osteopontin is also elevated in other cancers and inflammatory conditions, limiting its specificity.

Fibulin-3 is a glycoprotein that has shown promise in differentiating mesothelioma patients from healthy individuals and those with asbestos exposure but no malignancy. Fibulin-3 can be measured in both blood and pleural effusion fluid. Research suggests it may be particularly useful in early detection, though larger validation studies are needed.

Tissue-Based Biomarkers and Immunohistochemistry

When pathologists examine biopsy tissue, they use immunohistochemistry (IHC) to identify specific proteins on the cell surface. Several tissue biomarkers help confirm a mesothelioma diagnosis and distinguish it from other cancers. Calretinin, WT-1 (Wilms' tumor 1), cytokeratin 5/6, and D2-40 (podoplanin) are typically positive in mesothelioma cells.

Conversely, markers such as CEA, TTF-1, MOC-31, and BerEP4 are typically negative in mesothelioma but positive in lung adenocarcinoma and other cancers that can mimic mesothelioma. Pathologists use panels of these markers rather than any single one, because no individual marker is 100% specific for mesothelioma.

Emerging Biomarker Research

Current research is focused on developing multi-biomarker panels that combine several markers to improve diagnostic accuracy. By measuring multiple biomarkers simultaneously, researchers hope to achieve sensitivity and specificity levels that would make routine screening of high-risk populations feasible. Clinical trials are also exploring whether biomarker levels can predict which patients are most likely to respond to specific treatments, including immunotherapy.

Genetic and epigenetic biomarkers represent another frontier. Loss of the BAP1 gene, for example, is found in a significant percentage of mesothelioma tumors and can be detected through tissue analysis. Patients with BAP1-positive tumors may have a somewhat better prognosis. Liquid biopsy approaches that detect circulating tumor DNA (ctDNA) or tumor-derived exosomes in blood are also under investigation as potential non-invasive diagnostic and monitoring tools.

Biomarkers and Your Legal Case

While biomarkers are primarily a medical tool, they can support a legal claim by providing additional objective evidence of your mesothelioma diagnosis. Biomarker test results, along with pathology reports and imaging studies, become part of the medical record that forms the foundation of any compensation claim. If you have been diagnosed with mesothelioma, an experienced attorney can explain how your medical evidence supports your legal options.